Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EwiSarc

Financiado

Cerrado

A novel in vivo platform to study and target undruggable Ewing onco chimera.

Development of efficient therapeutic strategies in the past years has drastically reduced the lethality of several common types of pediatric and juvenile form of cancer such as leukemia, lymphoma and brain tumors. Such a tremendou... ver más

30/04/2019

UNITN

180K€

Presupuesto del proyecto: 180K€

Líder del proyecto

UNIVERSITA DEGLI STUDI DI TRENTO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-04-30

MSCA-IF-2016: Individual Fellowships

I+D

Cerrada hace 8 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UNITN

180.28K€ | Lider

Proyectos interesantes

PID2021-122828OB-I00

Medical Technol...

Oncology

194K€ Cerrado

SAF2009-10158

Medical Technol...

Data Science

133K€ Cerrado

PID2021-124716OB-I00

Medical Technol...

Genetics

321K€ Cerrado

PedSarc

Medical Technol...

Data Science

1M€ Cerrado

Cancer-Harakiri

Medical Technol...

Data Science

2M€ Cerrado

TARGETSS

Medical Technol...

Data Science

176K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 25 meses Fecha Inicio: 2017-03-17
Fecha Fin: 2019-04-30

Líder del proyecto

UNIVERSITA DEGLI STUDI DI TRENTO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 180K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Development of efficient therapeutic strategies in the past years has drastically reduced the lethality of several common types of pediatric and juvenile form of cancer such as leukemia, lymphoma and brain tumors. Such a tremendous success, however, does not include sarcomas treatment, whose mortality rate remains the same as twenty years ago. Ewing sarcoma is a childhood cancer with a relatively low incidence, with 3 cases/million/year. The initial oncogenic event is represented by a balanced chromosomal translocation originating a transcription factor chimeric onco-protein. Notably, 90% of Ewing sarcoma patients are characterized by the fusion between EWS and FLI1 genes. From a therapeutic point of view, as exclusive hallmark of tumor cells and driving force of the disease, the onco-chimera protein represents an ideal target, even though transcription factor onco-proteins are classified as undruggable from a conventional pharmacological point of view, lacking in their structure convenient targeting pockets. This project aims to break this dogma through the following steps: 1. Generation of an in vivo genetic platform based on an innovative ex vivo-in vitro-in vivo approach that will allow us to accurately recapitulate in mice Ewing sarcomagenesis; 2. Characterization in vivo and in vitro of those mechanisms and pathways that are essential for the tumorigenic process; and finally, 3. Identification of druggable targets whose fine-tuning will tear down Ewing sarcoma lethality by promoting onco-chimera degradation. The success of this project will not only lead to the development of new therapies against Ewing sarcoma, but also to the development of a novel platform which will be easily exported to other tumors driven by undruggable onco-chimeras.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores